Non-Small Cell Lung Cancer

We recommend

Brigatinib in the Therapy of Pretreated Patients with Advanced ALK-Positive NSCLC

22. 12. 2022 Source: Non-Small Cell Lung Cancer

A French study analyzed clinical data of pretreated ALK-positive patients with advanced non-small cell lung cancer (NSCLC) and examined the efficacy of next-generation ALK inhibitors –⁠ brigatinib, followed by lorlatinib –⁠ in real-world clinical practice.

Brigatinib in Patients with ALK+ NSCLC –⁠ Final Results of the J-ALTA Clinical Study

At this year's American Society of Clinical Oncology (ASCO) conference held in Chicago in early…

12. 9. 2022 Source: Non-Small Cell Lung Cancer

Impact of Depth of Treatment Response on Outcomes of ALK+ NSCLC Treatment with Brigatinib and Crizotinib

Brigatinib inhibits anaplastic lymphoma kinase (ALK) and its notable advantage is its strong effect…

12. 9. 2022 Source: Non-Small Cell Lung Cancer

Articles on this topic

From Biomarker Testing to NSCLC Treatment Selection

During a satellite symposium at this year's European Lung Cancer Congress (ELCC 2022), Prof.…

23. 5. 2022 Source: Non-Small Cell Lung Cancer

Efficacy of Brigatinib in Patients with Metastatic NSCLC −⁠ Real-World Clinical Data

The journal Lung Cancer published the results of a retrospective analysis of the efficacy of…

29. 11. 2021 Source: Non-Small Cell Lung Cancer

statistiky business grafy kancelář práce studie

Brigatinib in the Therapy of ALK-Positive NSCLC in Patients Refractory to Crizotinib Therapy –⁠ Results of the Final Analysis of Clinical Studies

Previously published results of clinical studies have shown that in patients refractory to…

9. 9. 2021 Source: Non-Small Cell Lung Cancer

Brigatinib in the Therapy of ALK-Positive NSCLC –⁠ First Results of the J-ALTA Study

Brigatinib is an anaplastic lymphoma kinase (ALK) inhibitor with broad and potent activity…

9. 9. 2021 Source: Non-Small Cell Lung Cancer

Current Results of Brigatinib in the Treatment of Lung Cancer

The results of the primary analysis showed a significant extension of PFS in patients with…

4. 6. 2021 Source: Non-Small Cell Lung Cancer

Brigatinib vs. Crizotinib in the Treatment of ALK-Positive NSCLC –⁠ Results of the Second Interim Analysis of the ALTA-1L Study

The anaplastic lymphoma kinase inhibitor brigatinib demonstrated superiority over crizotinib…

15. 2. 2021 Source: Non-Small Cell Lung Cancer

Good Efficacy of Brigatinib After Failure of 2nd Generation ALK Inhibitors

Brigatinib is commonly used in the treatment of ALK-positive non-small cell lung cancer…

15. 2. 2021 Source: Non-Small Cell Lung Cancer